Cancer News and Research

Latest Cancer News and Research

Doctor works to measure outcomes of provider care

Forbes profiles "the most powerful doctor you never heard of," a Yale cardiologist who does "outcomes research" in which he measures "how well doctors are doing in the real world, outside of controlled trials--what they are doing right, what they are doing wrong and what they are forgetting to do entirely."

10 Sep 2010

'Behind the counter' shop displays of cigarettes encourage smoking among youth

Young people believe 'behind the counter' shop displays of cigarettes encourage smoking and are considered "cool, fun and attractive" according to new research published in Health Promotion Practice.

10 Sep 2010

Good Start Genetics to develop pre-pregnancy genetic test with completed $18M Series A financing

Good Start Genetics, Inc., today announced the completion of an $18 million Series A financing. The proceeds of this financing will be used to complete the development and launch of the Company's pre-pregnancy genetic test, which utilizes advanced DNA sequencing technology to screen for a panel of genetic disorders including those recommended by the American Congress of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics (ACMG).

10 Sep 2010

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Varian Medical Systems is spotlighting its new TrueBeam™ medical linear accelerator for fast, powerful and efficient cancer treatments at the European Society for Therapeutic Radiology and Oncology exhibition in Barcelona next week. A fully-featured TrueBeam system will be the centerpiece of Varian's booth at the annual ESTRO meeting (Booth No. 320).

10 Sep 2010

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2010 fiscal year ended June 30, 2010.

10 Sep 2010

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.

10 Sep 2010

Structure of key protein for cellular signal transduction elucidated

Scientists of the Institute of Structural Biology of Helmholtz Zentrum München and the Technische Universität München have succeeded in elucidating the structure of an important region of the Sam68 protein. Sam68 is a key protein for cellular signal transduction. The Journal of Biological Chemistry has selected the report of these research findings as one of two "papers of the week" for its September 10, 2010 issue and has chosen the structural model as cover image.

10 Sep 2010

Nucletron to present innovative cancer treatment during ESTRO29

Nucletron, a leading provider of state of the art radiotherapy solutions for cancer treatment, today announced a large number of exciting innovations for precise cancer treatment that will be in the spotlight during ESTRO29 in Barcelona. The company will be showcasing the latest developments in cancer treatment solutions for both brachytherapy and external beam.

10 Sep 2010

Cancer Research UK launches world's first urban running lane on London's Southbank

Dawdling pedestrians test the patience of over a quarter of outdoor runners (27 per cent) according to a poll of 1,000 runners by Cancer Research UK, to launch its Run10k series. The results have been highlighted as the charity launches the world's first urban running lane on London's Southbank with the help of celebrity runner Nell McAndrew.

10 Sep 2010

Scottish government proposes minimum price to tackle alcohol misuse

The Scottish government has confirmed that it proposes to introduce a minimum price of 45p per unit of alcohol, in order to tackle alcohol misuse and prevent related illnesses.

10 Sep 2010

Using opioids at end-of-life care proves effective to control pain

Patients who choose to spend their last days at home with specialized care and monitoring can safely be given opioids to control pain and other symptoms without reducing survival time, according to a study published in Journal of Palliative Medicine (JPM), a peer-reviewed journal from Mary Ann Liebert, Inc.

10 Sep 2010

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Among Asian-Americans living in California, Laotian/Hmong-Americans have the lowest survival rates for the most common type of liver cancer, a new study by researchers with the UC Davis School of Medicine has found.

10 Sep 2010

Experts advise men to maintain record of prostate specific antigen test results for risk detection

Experts at The University of Texas MD Anderson Cancer Center advise men to keep a record of their prostate specific antigen (PSA) test results to help determine if they are at increased risk for prostate cancer.

10 Sep 2010

WHO regional meeting in South-East Asia addresses antimicrobial resistance, developing country access to medical devices

During the WHO's 63rd Regional Committee Session for South-East Asia in Bangkok on Wednesday the WHO called for enhanced "efforts at the national and international level to preserve the efficacy of antimicrobial agents through the rational use of antibiotics," Indian Express reports (Thacker, 9/9).

10 Sep 2010

VCU Pauley Heart Center to investigate portable, mechanical driver for powering artificial hearts

The Virginia Commonwealth University Medical Center is the lead institution in a national clinical trial of technology that will allow artificial heart patients to recuperate, rehabilitate and wait in the comfort of their own homes until a donor heart becomes available for transplant.

10 Sep 2010

Numerate awarded new contract by Defense Threat Reduction Agency

Numerate, Inc. announced today that it has been awarded a new three-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, to adapt its pioneering small-molecule drug design platform to the rapid design and optimization of drugs against biowarfare agents.

10 Sep 2010

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 – the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.

10 Sep 2010

NICE releases new guidelines to improve cancer care

The National Institute for Health and Clinical Excellence (NICE) has published a new guideline which should help to improve care for thousands of patients with advanced cancer that has spread from an unknown primary location.

10 Sep 2010

Translational Research issue focuses field of stem cell research, therapy

The use of stem cells for research and their possible application in the treatment of disease are hotly debated topics. In a special issue of Translational Research published this month an international group of medical experts presents an in-depth and balanced view of the rapidly evolving field of stem cell research and considers the potential of harnessing stem cells for therapy of human diseases including cardiovascular diseases, renal failure, neurologic disorders, gastrointestinal diseases, pulmonary diseases, neoplastic diseases, and type 1 diabetes mellitus.

10 Sep 2010

Shire announces expansion of Human Genetic Therapies pipeline

Shire plc, the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB class of molecules being developed by Acceleron Pharma Inc., a private biotechnology company based in Cambridge, Massachusetts.

10 Sep 2010

Cancer News and Research

Latest Cancer News and Research

Doctor works to measure outcomes of provider care

'Behind the counter' shop displays of cigarettes encourage smoking among youth

Good Start Genetics to develop pre-pregnancy genetic test with completed $18M Series A financing

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Structure of key protein for cellular signal transduction elucidated

Nucletron to present innovative cancer treatment during ESTRO29

Cancer Research UK launches world's first urban running lane on London's Southbank

Scottish government proposes minimum price to tackle alcohol misuse

Using opioids at end-of-life care proves effective to control pain

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Experts advise men to maintain record of prostate specific antigen test results for risk detection

WHO regional meeting in South-East Asia addresses antimicrobial resistance, developing country access to medical devices

VCU Pauley Heart Center to investigate portable, mechanical driver for powering artificial hearts

Numerate awarded new contract by Defense Threat Reduction Agency

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

NICE releases new guidelines to improve cancer care

Translational Research issue focuses field of stem cell research, therapy

Shire announces expansion of Human Genetic Therapies pipeline

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in